The Future of the 340B Program: 2023 Key Decisions
Foley
APRIL 13, 2023
” The resolution of these issues will have an enormous financial impact on the health care industry, including pharmaceutical manufacturers, 340B hospitals, and federal grantees. Starting in early 2021, multiple pharmaceutical manufacturers initiated litigation to challenge HRSA’s enforcement authority in this area.
Let's personalize your content